Skip to main content

Table 4 Overall survival, quality-adjusted life years and costs per patient, base case analysis

From: Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain

 

Undiscounted

Discounted

Palivizumab

No prophylaxis

Difference

Palivizumab

No prophylaxis

Difference

Life years

66.51

66.34

0.17

27.15

27.08

0.07

Quality-adjusted life years by RSV history

61.89

61.68

0.21

25.73

25.62

0.11

 No RSV

57.61

51.06

6.56

23.96

21.24

2.73

 MA-RSV

1.20

5.00

−3.80

0.49

2.07

−1.57

 RSV-H

3.08

5.63

−2.55

1.27

2.31

−1.05

Quality-adjusted life years by sequelae history

 No Sequelae

61.28

60.25

1.03

25.25

24.51

0.74

 Asthma

0.16

0.34

−0.18

0.13

0.27

−0.14

 Allergic sensitization

0.33

0.84

−0.51

0.26

0.66

−0.40

 Asthma and allergic sensitization

0.12

0.24

−0.12

0.09

0.19

−0.10

Costs

€ 4731

€ 3220

€ 1511

€ 4574

€ 2881

€ 1693

 Prophylaxis costs

€ 3100

€ 0

€ 3100

€ 3100

€ 0

€ 3100

 MA-RSV: Medical care

€ 2

€ 9

-€ 7

€ 80

€ 334

-€ 254

 MA-RSV: Sequelae

€ 100

€ 418

-€ 318

€ 2

€ 9

-€ 7

 RSV-H: Medical care

€ 1063

€ 1941

-€ 879

€ 1042

€ 1904

-€ 862

 RSV-H: Sequelae

€ 440

€ 803

-€ 364

€ 326

€ 595

-€ 269

 RSV-H: Nosocomial

€ 27

€ 49

-€ 22

€ 27

€ 49

-€ 22

  1. Abbreviations: RSV, respiratory syncytial virus; MA-RSV, medically attended RSV infection; RSV-H, RSV infection resulting in hospitalization